kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
8,245
JPY
-227
(-2.68%)
Dec 5, 12:48 pm JST
53.15
USD
Dec 4, 10:48 pm EST
Result
PTS
outside of trading hours
8,234.8
Dec 5, 12:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.18
Yield
3.03%
Margin Trading Ratio
5.77
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
8,390 JPY 54.08 USD
Previous Close Dec 4
8,472 JPY 54.52 USD
High Dec 5, 9:00 am
8,393 JPY 54.10 USD
Low Dec 5, 10:18 am
8,228 JPY 53.04 USD
Volume
612,300
Trading Value
5.08B JPY 0.03B USD
VWAP
8288.44 JPY 53.43 USD
Minimum Trading Value
824,500 JPY 5,315 USD
Market Cap
13.84T JPY 0.09T USD
Number of Trades
2,691
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
6,917
1-Year High Aug 8, 2025
42,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 180,500 635,000 3.52
Nov 21, 2025 171,300 599,900 3.50
Nov 14, 2025 163,300 650,100 3.98
Nov 7, 2025 115,800 910,800 7.87
Oct 31, 2025 56,800 1,571,100 27.66
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.